For the quarter ended September 2025, Sotera Health Company (SHC) reported revenue of $311.31 million, up 9.1% over the same period last year. EPS came in at $0.26, compared to $0.17 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $305.33 million, representing a surprise of +1.96%. The company delivered an EPS surprise of +18.18%, with the consensus EPS estimate being $0.22.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sotera Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues- Sterigenics: $192.85 million compared to the $190.27 million average estimate based on two analysts. The reported number represents a change of +9.8% year over year.
- Net Revenues- Nelson Labs: $55.66 million versus $57.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5% change.
- Net Revenues- Nordion: $62.81 million versus the two-analyst average estimate of $57.08 million. The reported number represents a year-over-year change of +22.4%.
View all Key Company Metrics for Sotera Health here>>>
Shares of Sotera Health have returned +2.4% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sotera Health Company (SHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
